Results 131 to 140 of about 1,090 (156)

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

J Clin Endocrinol Metab
Wolf J, Lorenz K, Othman AE, Beck A, Michel HM, Grauhan L, Elflein H, Luffy M, Eckstein A, Lahner H, Schittkowski M, Horn M, Lagrèze WA, Bleul T, Pitz S, Vorländer C, Pieterse CC, Porter B, Clemens A, Draikiwicz S, Reinhardt M, Kahaly GJ.   +21 more
europepmc   +1 more source

Treatment of thyroid orbitopathy (Graves Orbitopathy) based on EUGOGO 2021 guidelines, with focus on Polish reality [PDF]

Lekarz Wojskowy, 2022
Europejskie wytyczne leczenia orbitopatii tarczycowej zostały zaktualizowane w 2021 r., wprowadzając modyfikacje dotychczas stosowanego leczenia. Otworzyły również drogę nowym terapeutykom mogącym służyć jako alternatywa standardowego postępowania.
Grzegorz Kaminski, Marek Saracyn, Adam Daniel Durma   +2 more
exaly   +8 more sources

PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012

British Journal of Ophthalmology, 2015
The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time.Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres.
Raluca Maria Furnica, Claudio Marcocci, Petros Perros   +2 more
exaly   +8 more sources

Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone

Journal of the Endocrine Society, 2021
Abstract Background: The European Group on Graves’ Orbitopathy (EUGOGO) recommends intravenous methylprednisolone (IVMP) as the first line treatment for moderate-to-severe active thyroid eye disease (TED). While many studies with varying doses of IVMP have reported improvements in inflammation, via clinical activity score (CAS) reduction,
Chris Cameron
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy

Thyroid, 2008
Luigi Bartalena, Lelio Baldeschi, Alison J. Dickinson, Anja Eckstein, Pat Kendall-Taylor, Claudio Marcocci, Maarten P. Mourits, Petros Perros, Kostas Boboridis, Antonella Boschi, Nicola Curro, Chantal Daumerie, George J. Kahaly, Gerasimos Krassas, Carol M. Lane, John H.
Petros Perros, Simon Pearce, Luigi Bartalena   +2 more
exaly   +3 more sources

Innovazioni nelle linee guida EUGOGO per il trattamento dell’orbitopatia basedowiana

L Endocrinologo, 2022
Francesco Vermiglio, Mariacarla Moleti
exaly   +2 more sources

EUGOGO Anniversary Symposium

2021
exaly   +2 more sources

Editorial: Will the EUGOGO Predictive Score for Graves’ Orbitopathy Be Useful for Management?

Clinical Thyroidology, 2018
exaly   +2 more sources

Development of Cooperation between Endocrinologists and Ophthalmologists: European Group on Graves’ Orbitopathy (EUGOGO)

Acta Endocrinologica, 2014
exaly   +2 more sources